Infectious Endocarditis by Pseudomonas aeruginosa in an Immunocompetent Adult

被引:2
|
作者
Dimadi, Ioanna I. Yglesias [1 ]
Murillo, Marcelo Rodriguez [2 ]
Zuniga, Manuel A. Villalobos [3 ]
机构
[1] Univ Costa Rica, Gen Practice, San Jose, Costa Rica
[2] Hosp San Juan Dios, Cardiol, Caja Costarricense Seguro Social, San Jose, Costa Rica
[3] Hosp San Juan Dios, Infect Dis, Caja Costarricense Seguro Social, San Jose, Costa Rica
关键词
immunocompetence; bacteremia; nosocomial infection; infectious endocarditis; pseudomonas aeruginosa; RISK-FACTORS; BACTEREMIA; SURVEILLANCE;
D O I
10.7759/cureus.35072
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the following case review, we present a 49-year-old male without a history of injection drug (IDU) use nor any known structural heart disease, who developed left-sided pseudomonal infectious endocarditis. The only known risk factors were urinary tract infection (UTI) with secondary bacteremia and prolonged healthcare contact with admission to the intensive care unit. Infectious endocarditis (IE) is the infection of the endocardium. The official diagnosis can only be established after histological and microbiological studies confirm microorganism-colonized vegetations in the heart valves, but a clinical suspicion with high sensitivity and specificity can be approached with modified Duke's criteria. Even though structural heart disease is the major predisposing factor for IE, healthcare-associated IE has risen with the new therapeutic interventions. Transient bacteremia, which might result after various procedures, forms part of the factors causing healthcare-associated IE. Although both, community-acquired and hospital-acquired infections by Pseudomonas aeruginosa have been reported, pure community-acquired infections without previous exposure to the hospital or healthcare environment are extremely rare. Intensive care unit (ICU) patients are at special risk for this microbe. It is considered an important causative agent in ventilator/associated pneumonia, catheter-associated urinary tract infection (UTI), and catheter-associated bloodstream infections. IE by P. aeruginosa remains a rare form of IE. Though 95% of cases are associated with injection drug use (IDU), healthcare contact is becoming more important each day as the primary risk factor. The most common complications include abscesses in the ring and annulus, congestive heart failure (CHF), embolisms, inability to sterilize valves, splenic abscesses, recurrent bacteremia, and neurologic complications. This condition is highly fatal, with a mortality rate of over 73% for patients older than 30 years. Recommended antibiotic treatment for IE caused by P. aeruginosa consists of high-dose tobramycin in combination with antipseudomonal penicillin or high-dose ceftazidime, cefepime, or imipenem.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Carbapenem Resistant Pseudomonas aeruginosa Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes
    Qin, Jie
    Zou, Chengyun
    Tao, Jianmin
    Wei, Tian
    Yan, Li
    Zhang, Yufei
    Wang, Haiying
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 2301 - 2314
  • [42] Infectious Spondylitis with Bacteremia Caused by Roseomonas mucosa in an Immunocompetent Patient
    Kim, Kyong-Young
    Hur, Jaehyung
    Jo, Wonyong
    Hong, Jeongmin
    Cho, Oh-Hyun
    Kang, Dong Ho
    Kim, Sunjoo
    Bae, In-Gyu
    INFECTION AND CHEMOTHERAPY, 2015, 47 (03) : 194 - 196
  • [43] Left-sided infective endocarditis caused by Pseudomonas aeruginosa treated medically
    Melissa Ordonez, Karen
    Andrea Hernandez, Odismar
    Alberto Cortes, Jorge
    Jose Lopez, Maria
    Alfonso, Gladys
    Junca, Alejandro
    BIOMEDICA, 2010, 30 (02): : 164 - 169
  • [44] Identification of infectious Pseudomonas aeruginosa strains in an occupational saturation diving environment
    Ahlen, C
    Mandal, LH
    Iversen, OJ
    OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 1998, 55 (07) : 480 - 484
  • [45] A Case of Nosocomial Prosthetic Valve Endocarditis Due to Pseudomonas aeruginosa Associated With Complications
    Cesur, Salih
    Kaya-Kilic, Esra
    Oztoprak-Siyah, Ulku
    Ataman-Hatipoglu, Cigdem
    Ozsoy, Metin
    Yildiz, Oguzhan
    Kinikli, Sami
    KLIMIK JOURNAL, 2020, 33 (01) : 91 - 94
  • [46] Monotherapy or Combination Therapy? The Pseudomonas aeruginosa Conundrum
    Traugott, Kristi A.
    Echevarria, Kelly
    Maxwell, Pamela
    Green, Kay
    Lewis, James S., II
    PHARMACOTHERAPY, 2011, 31 (06): : 598 - 608
  • [47] Influence of Virulence Genotype and Resistance Profile in the Mortality of Pseudomonas aeruginosa Bloodstream Infections
    Pena, Carmen
    Cabot, Gabriel
    Gomez-Zorrilla, Silvia
    Zamorano, Laura
    Ocampo-Sosa, Alain
    Murillas, Javier
    Almirante, Benito
    Pomar, Virginia
    Aguilar, Manuela
    Granados, Ana
    Calbo, Esther
    Rodriguez-Bano, Jesus
    Rodriguez-Lopez, Fernando
    Tubau, Fe
    Martinez-Martinez, Luis
    Oliver, Antonio
    CLINICAL INFECTIOUS DISEASES, 2015, 60 (04) : 539 - 548
  • [48] Evaluation of Selected Parameters of the Specific Immune Response against Pseudomonas aeruginosa Strains
    Dzik, Michal
    Aebisher, David
    Olender, Alina
    Tabarkiewicz, Jacek
    CELLS, 2022, 11 (01)
  • [49] Recurrent Pseudomonas aeruginosa Bacteremia Report and Analysis of 19 Episodes and Review of the Literature
    Ek, Juliann
    Tatineni, Vineeth
    Myers, David
    Myers, Joseph
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2021, 29 (03) : e133 - e139
  • [50] Pseudomonas aeruginosa bacteremia: Targeting virulent phenotypes?
    Kipnis, Eric
    Faure, Karine
    CRITICAL CARE MEDICINE, 2012, 40 (04) : 1354 - 1355